IRhythm Technologies Company Insiders
| IRTC Stock | USD 144.21 4.20 2.83% |
IRhythm Technologies employs about 2 K people. The company is managed by 18 executives with a total tenure of roughly 20 years, averaging almost 1.0 years of service per executive, having 111.11 employees per reported executive. Evaluation of IRhythm Technologies' management performance can provide insight into the firm performance.
| Mark Day President Executive Vice President of Research and Development |
| David Vort President Executive Vice President of Sales |
IRhythm Technologies' latest congressional trading
Congressional trading in companies like iRhythm Technologies, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in IRhythm Technologies by those in governmental positions are based on the same information available to the general public.
| 2025-09-12 | Senator Richard Blumenthal | Acquired Under $15K | Verify |
IRhythm Technologies Management Team Effectiveness
The company has return on total asset (ROA) of (0.0308) % which means that it has lost $0.0308 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5315) %, meaning that it created substantial loss on money invested by shareholders. IRhythm Technologies' management efficiency ratios could be used to measure how well IRhythm Technologies manages its routine affairs as well as how well it operates its assets and liabilities.The majority of iRhythm Technologies outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in IRhythm Technologies to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in iRhythm Technologies. Please pay attention to any change in the institutional holdings of iRhythm Technologies as this could imply that something significant has changed or is about to change at the company. On September 12, 2025, Senator Richard Blumenthal of US Senate acquired under $15k worth of iRhythm Technologies's common stock.
Some institutional investors establish a significant position in stocks such as IRhythm Technologies in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of IRhythm Technologies, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
IRhythm Technologies Workforce Comparison
iRhythm Technologies is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 107,204. IRhythm Technologies claims roughly 2,000 in number of employees contributing just under 2% to equities under Health Care industry.
The company has Profit Margin (PM) of (0.07) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.02) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.02. IRhythm Technologies Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific IRhythm Technologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on IRhythm Technologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, IRhythm Technologies insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Chad Patterson over a week ago Disposition of 1300 shares by Chad Patterson of IRhythm Technologies at 125.0 subject to Rule 16b-3 | ||
Chad Patterson over a week ago Acquisition by Chad Patterson of 25546 shares of IRhythm Technologies subject to Rule 16b-3 | ||
Daniel Wilson over two months ago Disposition of 2341 shares by Daniel Wilson of IRhythm Technologies at 108.77 subject to Rule 16b-3 | ||
Talwalkar Abhijit Y over six months ago Disposition of 5312 shares by Talwalkar Abhijit Y of IRhythm Technologies at 10.71 subject to Rule 16b-3 | ||
Chad Patterson over six months ago Disposition of 2555 shares by Chad Patterson of IRhythm Technologies at 158.97 subject to Rule 16b-3 | ||
Turakhia Minang over six months ago Disposition of 1420 shares by Turakhia Minang of IRhythm Technologies at 145.41 subject to Rule 16b-3 | ||
Freeman Sean Clinton over six months ago Insider Trading | ||
Marc Rosenbaum over six months ago Disposition of 696 shares by Marc Rosenbaum of IRhythm Technologies at 140.21 subject to Rule 16b-3 |
IRhythm Technologies Notable Stakeholders
An IRhythm Technologies stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as IRhythm Technologies often face trade-offs trying to please all of them. IRhythm Technologies' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting IRhythm Technologies' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Quentin Blackford | CEO President | Profile | |
| Mark Day | Executive Vice President of Research and Development | Profile | |
| David Vort | Executive Vice President of Sales | Profile | |
| Brian Lawrence | Executive CTO | Profile | |
| Stephanie Zhadkevich | Director Relations | Profile | |
| Sean Freeman | Executive Development | Profile | |
| Chad Patterson | Chief Officer | Profile | |
| Brice CPA | Chief Officer | Profile | |
| Mazi Kiani | VP Regulatory | Profile | |
| Daniel Wilson | Executive Relations | Profile | |
| Mintu MD | Chief Officer | Profile | |
| MS MD | Chief Technologies | Profile | |
| Mervin Smith | Executive Operations | Profile | |
| Patrick JD | Chief Counsel | Profile | |
| Douglas Devine | Executive Advisor | Profile | |
| Marc Rosenbaum | Senior Officer | Profile | |
| Reyna Fernandez | Ex Officer | Profile | |
| Sumi Shrishrimal | Executive Officer | Profile |
About IRhythm Technologies Management Performance
The success or failure of an entity such as iRhythm Technologies often depends on how effective the management is. IRhythm Technologies management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of IRhythm management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the IRhythm management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram monitoring products for patients at risk for arrhythmias in the United States. The company was incorporated in 2006 and is headquartered in San Francisco, California. Irhythm Technologies operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 1700 people.
Please note, the presentation of IRhythm Technologies' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, IRhythm Technologies' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of IRhythm Technologies' management manipulating its earnings.
IRhythm Technologies Workforce Analysis
Traditionally, organizations such as IRhythm Technologies use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare IRhythm Technologies within its industry.IRhythm Technologies Manpower Efficiency
Return on IRhythm Technologies Manpower
| Revenue Per Employee | 295.9K | |
| Revenue Per Executive | 32.9M | |
| Net Loss Per Employee | 56.6K | |
| Net Loss Per Executive | 6.3M | |
| Working Capital Per Employee | 267.4K | |
| Working Capital Per Executive | 29.7M |
Complementary Tools for IRhythm Stock analysis
When running IRhythm Technologies' price analysis, check to measure IRhythm Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IRhythm Technologies is operating at the current time. Most of IRhythm Technologies' value examination focuses on studying past and present price action to predict the probability of IRhythm Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IRhythm Technologies' price. Additionally, you may evaluate how the addition of IRhythm Technologies to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Stocks Directory Find actively traded stocks across global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |